Literature DB >> 28665008

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation.

Diane A van der Biessen1, Peer G van der Helm2, Dennis Klein1, Simone van der Burg3, Ron H Mathijssen1, Martijn P Lolkema1, Maja J de Jonge1.   

Abstract

OBJECTIVE: This study aimed to understand how hope and motivation of patients considering phase I trial participation are affected by psychological factors such as coping strategies and locus of control (LoC) and general well-being as measured by the quality of life (QoL).
METHODS: An exploratory cross-sectional study was performed in patients with incurable cancer (N = 135) referred to our phase I unit for the first time. Patients were potentially eligible for phase I trial participation and participated in our study while deliberating phase I trial participation. We used questionnaires on hope, motivation to participate, coping, LoC, and QoL. To investigate the nature and magnitude of the relationships between the scales, a structural equation modeling (SEM) was fitted to the data.
RESULTS: Hope significantly predicted the motivation to participate in phase I trials. Predictors of hope were a combination of flexible and tenacious goal pursuit (both P < .01), internal LoC (P < .01), and QoL (P < .01). The SEM showed an exact fit to the data, using a null hypothesis significance test: chi-square (8) = 9.30, P = .32.
CONCLUSIONS: Patients considering phase I trial participation seem to use a pact of tenacious and flexible coping and control to stay hopeful. Furthermore, hope and QoL positively affected each other. The psychological pact may promote an adaptation enabling them to adjust to difficult circumstances by unconsciously ignoring information, called dissonance reduction. This mechanism may impair their ability to provide a valid informed consent. We suggest including a systematic exploration of patients' social context and values before proposing a phase I trial.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  SEM; coping; hope; incurable cancer; motivation; oncology phase I trials; quality of life

Mesh:

Year:  2017        PMID: 28665008     DOI: 10.1002/pon.4487

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  6 in total

Review 1.  Hope therapy in cancer patients: a systematic review.

Authors:  Hamed Salimi; Haniyeh Bashi Zadeh Fakhar; Mohammad Hadizadeh; MohammadEsmaeil Akbari; Neda Izadi; Reza MohamadiRad; Hosna Akbari; Ramtin Hoseini
Journal:  Support Care Cancer       Date:  2022-01-25       Impact factor: 3.603

2.  Investigating the Mediatory Role of Hope and Shame in the Relationship between Caregiver Burden and Quality of Life of Patients with Cancer.

Authors:  Touraj Shahvand; Mehdi Reza Sarafraz
Journal:  South Asian J Cancer       Date:  2021-03-14

3.  Predictors of Quality of Life Change in Head-and-Neck Cancer Survivors during Concurrent Chemoradiotherapy: A Prospective Study.

Authors:  Ya-Hui Tsan; Shin-Huey Wung; Ming-Wei Lin; Wen-Liang Lo; Ya-Jung Wang
Journal:  Asia Pac J Oncol Nurs       Date:  2021-03-12

4.  Integrating Palliative Care for Patients on Clinical Trials: Opportunities for Oncology Nurses.

Authors:  Betty Ferrell; Tami Borneman; Anna Cathy Williams; Angela Scardina; Patricia Fischer; Thomas J Smith
Journal:  Asia Pac J Oncol Nurs       Date:  2020-06-26

5.  Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT).

Authors:  Liza G G van Lent; Nicole K Stoel; Julia C M van Weert; Jelle van Gurp; Maja J A de Jonge; Martijn P Lolkema; Eelke H Gort; Saskia M Pulleman; Esther Oomen-de Hoop; Jeroen Hasselaar; Carin C D van der Rijt
Journal:  BMC Palliat Care       Date:  2019-11-29       Impact factor: 3.234

6.  Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing.

Authors:  Liza G G van Lent; Maja J A de Jonge; Mirte van der Ham; Marjolein van Mil; Eelke H Gort; Jeroen Hasselaar; Esther Oomen-de Hoop; Carin C D van der Rijt; Julia C M van Weert; Martijn P Lolkema
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.